Bausch Health Companies Inc. (BHC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.01 |
| Open | 5.99 |
| Bid | 6.30 x 900 |
| Ask | 6.27 x 800 |
| Day's Range | 5.90 - 6.31 |
| 52 Week Range | 4.00 - 29.59 |
| Volume | |
| Avg. Volume | 7,616,693 |
| Market Cap | 2.277B |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | 44.86 |
| EPS (TTM) | 0.14 |
| Earnings Date | Oct 31, 2022 - Nov 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 10, 2010 |
| 1y Target Est | 15.18 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BHC
Related Research
- Bausch Health Companies Inc.Analyst Report: Bausch Health Companies Inc.Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Bausch+Lomb (45% of revenue), Salix Pharmaceuticals (24%), international pharma (14%), ortho dermatology (7%), and diversified products (10%). Bausch is the market leader in consumer visioncare in India and China and the fourth-largest visioncare company by sales in the United States.RatingFair ValueEconomic Moat5 days agoMorningstar
- Zacks
Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision
Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.
- InvestorPlace
7 Stock Price Predictions That Are Actually Worth Listening To
Generally, Wall Street stock price predictions are hardly the best source of investing ideas that have the most upside. Investors should interpret stocks that analysts claim have the most upside carefully. Often, either the analyst is too optimistic about the company’s fair value or the stock market is wrong. Investors may pick stocks with the most promising price predictions by reviewing their stock scores. As difficult as it is to make stock price predictions based on the numbers alone, someti
- CNW Group
Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit
Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, consistent with the company's July 28, 2022, press release, the U.S. District Court of Delaware has issued a decision in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. finding certain XIFAXAN® (rifaximin) 550 mg HE patents valid and infringed and certain XIFAXAN composition and IBS-D patents invalid. As previously stated, the Company will
